Current Month 2011
Article Features
  Dense Breasts Can Nearly Double the Risk of Breast Cancer Recurrence
Breast Cancer Screening and Better Treatment Both Help to Save Significant Numbers of Lives
Pregnancy is Safe for Women with Estrogen Receptor Positive Breast Cancer
MRI Screening for Women with a Family History of Breast Cancer But No Genetic Predisposition is Expensive But Could Be Cost-Effective for Some
Understanding Individual Genetic Variation Can Help Predict Chemotherapy Side Effects
Ultrasound-Guided Surgery is the Best Way to Remove Breast Tumors and Should Become the New Standard of Care
New Genomic Test Spares Patients Chemotherapy with No Adverse Effect on Survival
Everolimus Plus Exemestane Improves Bone Health in Post-Menopausal Women with Advanced Breast Cancer
Radiotherapy for DCIS Still Protects Against Recurrence after 15 Years
Cancer Cells in Blood Predict Chances of Survival and Can Help Target Breast Cancer Treatment
Non-Drug Treatments Help Alleviate Symptoms of Treatment-Induced Menopause in Breast Cancer Patients
20-Year Results from National Breast Cancer Screening Program Show Significant Drop in Deaths, Limited Harm and Reasonable Costs
Overweight and Obese Women at Greater Risk of Breast Cancer Recurrence Even After Chemotherapy Dose Adjustment


Overweight and Obese Women at Greater Risk of Breast Cancer Recurrence Even After Chemotherapy Dose Adjustment

Women who are overweight or obese when they are diagnosed with breast cancer are at higher risk of cancer recurrence or related death than are leaner women, according to a new study presented to the 8th European Breast Cancer Conference (EBCC-8) in Vienna, Austria. This finding held true even though the study mandated that chemotherapy dosage be adjusted for body weight, and adds further to the evidence that lifestyle factors can influence cancer prognosis, a researcher told the conference.

Dr. Jennifer Ligibel, a medical oncologist at the Dana-Farber Cancer Institute in Boston and an Associate Professor at Harvard Medical School, and colleagues, studied data from 1909 patients who were enrolled into a study called CALGB 9741 between 1997 and 1999. The study was set up to investigate different dosing schedules for adjuvant chemotherapy in patients where cancer cells were found in the lymph nodes (node-positive cancer). The presence of such cells in the lymph nodes means that there is a higher chance of cancer returning after surgery.

After extracting height and weight data from the patient records, they went on to evaluate the relationship between body mass index (BMI) with relapse-free survival (RFS) and overall survival (OS). 1.2% of the patients were underweight, 32.6% normal weight, 32.9% overweight, and 33.3% obese. 49% of patients were menopausal, 65% had estrogen-receptor positive cancers, where the presence of estrogen encourages the tumor to grow, and 70% received the estrogen-receptor blocking treatment, tamoxifen.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon